FindTrial
Sign In

S-equol

DRUG8 trials

Sponsors

Ausio Pharmaceuticals, LLC, The University of Texas Health Science Center at San Antonio, Pharmavite LLC, Akira Sekikawa, University of Colorado, Denver

Conditions

Arterial StiffnessBenign Prostatic HyperplasiaBreast CancerChronic Kidney DiseasesCognitive DeclineHealthyMenopauseVascular Function

Early Phase 1

S-equol in Women With Triple Negative Breast Cancer
CompletedNCT02352025
The University of Texas Health Science Center at San AntonioBreast Cancer
Start: 2015-04-15End: 2020-06-30Updated: 2020-07-22

Phase 1

Safety and Pharmacokinetic Study of S-Equol in Healthy Volunteers
CompletedNCT00787007
Ausio Pharmaceuticals, LLCHealthy
Start: 2008-09-30End: 2008-12-31Updated: 2012-01-20
Multi-Dose Safety and Pharmacokinetic Study of S-Equol in Healthy Volunteers
CompletedNCT00998920
Ausio Pharmaceuticals, LLCHealthy
Start: 2008-12-31End: 2009-04-30Updated: 2012-07-12

Phase 2

Efficacy and Safety of S-Equol on Men With Benign Prostatic Hyperplasia
CompletedNCT00962390
Ausio Pharmaceuticals, LLCBenign Prostatic Hyperplasia
Start: 2009-06-30End: 2016-01-31Updated: 2017-05-19
Efficacy and Safety of S-equol on Vasomotor Symptoms in Menopausal Patients
CompletedNCT00962585
Ausio Pharmaceuticals, LLCMenopause
Start: 2010-06-30End: 2011-11-30Updated: 2014-04-08
Effect of Equol Supplementation on Arterial Stiffness and Cognition in Healthy Volunteers
Active, not recruitingNCT05741060
Akira SekikawaArterial Stiffness, Cognitive Decline, White Matter Lesions
Start: 2023-06-29End: 2027-01-30Updated: 2026-08-20
Acute Equol Supplementation and Vascular Function in Women With and Without CKD
RecruitingNCT06128278
University of Colorado, DenverChronic Kidney Diseases, Vascular Function, Women
Start: 2023-03-07End: 2026-12-31Target: 38Updated: 2025-09-30

Unknown Phase

A Nutritional Supplement on Vasomotor Symptoms in Women
CompletedNCT04516304
Pharmavite LLCMenopause
Start: 2019-03-27End: 2020-05-22Updated: 2024-04-04

Related Papers

Novel estrogen receptor beta agonist S-equol decreases tumor proliferation in patients with triple negative breast cancer (TNBC).
Journal of Clinical Oncology2020-05-2011 citations